Scholarlink

Purpose <p>Human epidermal growth factor receptor 2 (HER2)-low breast cancer has been recognized as a distinct biological subset within HER2-negative breast cancer. This study aimed to examine the differences in sentinel lymph node metastasis (SLNM) rates and prognosis between HER2-low and HER2-zero breast cancers.</p> Methods <p>This retrospective study evaluated 965 estrogen receptor-positive, HER2-negative breast cancer patients who underwent sentinel lymph node biopsy at Osaka Metropolitan University Hospital. Clinicopathological characteristics, SLNM rates, and prognostic outcomes were compared between patients with HER2-low and with HER2-zero breast cancers.</p> Results <p>The SLNM rate was significantly higher in the HER2-low group than in the HER2-zero group (<i>p</i> = 0.039). However, disease-free survival (DFS), recurrence-free interval (RFI), overall survival, and breast cancer-specific survival were not significantly different between the two groups. In subgroup analysis excluding macrometastases, DFS and RFI were significantly longer in the HER2-low breast cancer group.</p> Conclusion <p>HER2-low breast cancer exhibits a higher SLNM rate, suggesting unique biological behavior. However, its overall prognosis remains similar to that of HER2-zero breast cancer, with potential prognostic advantages in select subgroups.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Differences in Sentinel lymph node biopsy outcomes and prognosis between HER2-low and HER2-zero breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月6日

查看全文
  • Koji Takada,
  • Shinichiro Kashiwagi,
  • Mariko Nishikawa,
  • Asuka Kochi,
  • Chika Watanabe,
  • Haruhito Kinoshita,
  • Kana Ogisawa,
  • Masatsune Shibutani,
  • Tamami Morisaki

摘要

Purpose

Human epidermal growth factor receptor 2 (HER2)-low breast cancer has been recognized as a distinct biological subset within HER2-negative breast cancer. This study aimed to examine the differences in sentinel lymph node metastasis (SLNM) rates and prognosis between HER2-low and HER2-zero breast cancers.

Methods

This retrospective study evaluated 965 estrogen receptor-positive, HER2-negative breast cancer patients who underwent sentinel lymph node biopsy at Osaka Metropolitan University Hospital. Clinicopathological characteristics, SLNM rates, and prognostic outcomes were compared between patients with HER2-low and with HER2-zero breast cancers.

Results

The SLNM rate was significantly higher in the HER2-low group than in the HER2-zero group (p = 0.039). However, disease-free survival (DFS), recurrence-free interval (RFI), overall survival, and breast cancer-specific survival were not significantly different between the two groups. In subgroup analysis excluding macrometastases, DFS and RFI were significantly longer in the HER2-low breast cancer group.

Conclusion

HER2-low breast cancer exhibits a higher SLNM rate, suggesting unique biological behavior. However, its overall prognosis remains similar to that of HER2-zero breast cancer, with potential prognostic advantages in select subgroups.